Varicose veins are common and their management has undergone a number of changes over the years. Surgery has been the traditional treatment option, but towards the 21st century, new endovenous thermal ablation techniques, namely, radiofrequency ablation and endovenous laser ablation, were introduced which have revolutionised the way varicose veins are treated. These minimally invasive techniques are associated with earlier return to normal activity and less pain, as well as enabling procedures to be carried out as day cases. They are, however, also known to cause a number of sideeffects and involve infiltration of tumescent fluid which can cause discomfort. Non-thermal, non-tumescent methods are believed to be the answer to these unwelcome effects. Ultrasound-guided foam sclerotherapy is one such non-thermal, non-tumescent method and, despite a possible lower occlusion, has been shown to improve the quality of life of patients. The early results of two recently launched non-thermal, non-tumescent methods, mechanochemical ablation and cyanoacrylate glue, are promising and are discussed.
The management of varicose veins has changed drastically over recent years, but the ideal treatment remains elusive. Traditionally, varicose veins have been treated with surgical ligation and stripping under general anaesthetic, but, over the past decade, minimally invasive techniques and local anaesthesia have become increasingly popular and indeed preferred. 1 These have also been shown to be associated with less peri-procedural pain and an earlier return to normal function. 1 These endovenous techniques are cost-effective, especially when performed in an outpatient or 'office-based' setting. 2 The National Institute of Clinical Excellence (NICE) guidelines, published in July 2013, recommended the use of endovenous thermal ablation techniques, namely radiofrequency ablation (RFA) or endovenous later ablation (EVLA), as first-line treatment for truncal vein reflux. 3, 4 Occlusion rates of greater than 90% have been demonstrated in studies looking at these two methods at up to 2 years of follow up. 1, [5] [6] [7] .
However, because they make use of thermal energy to denature the venous wall, they have the potential of causing pain, skin burns, skin pigmentation, nerve damage and, even, arteriovenous fistula formation. 8, 9 To minimise these possible complications, tumescent anaesthesia has to be infiltrated around the vein to be treated. This, in turn, can be a source of discomfort to patients.
Non-thermal, non-tumescent (NTNT) methods, hence, seem to be able to provide an alternative solution to the problems raised by these thermal techniques. In this review, we will be discussing the various NTNT techniques currently available. the treatment of smaller veins, but was not suitable for larger ones as the air would position itself on the upper side of the vein, thereby preventing contact with endothelium. This led to high rates of treatment failure. In the 1990s modern foam sclerotherapy was created, when new methods of transforming liquid sclerosants into foam were described. 12 Sclerosing agents used as foam displace venous blood and increase endothelial contact, thereby augmenting their sclerosing power. 13 One of the most widely used technique to produce foam is the Tessari method, which requires two syringes and a three-way tap and enables the production of a stable and compact foam. 13 The optimal formulation was found to be one part liquid sclerosant to four parts air. 13 Evolution of the technique has continued, with the introduction of ultrasound guidance (ultrasound-guided foam sclerotherapy) or catheter directed foam sclerotherapy for the treatment of truncal veins. [14] [15] [16] Two of the most common sclerosing solutions available are sodium tetradecylsulphate (STS) and polidocanol (POL).
Yamaki et al. 17 demonstrated the superiority of foam over liquid sclerosants in a comparative nonrandomised study of ultrasound-guided sclerotherapy using either foam or liquid. Sixty-two women, with mean age of 54.6 years, were recruited and received polidocanol either as foam or liquid to treat great saphenous vein (GSV) insufficiency. At 12 months' follow-up, approximately 68% of patients receiving foam sclerotherapy had evidence of complete occlusion compared to 17.5% of those in the liquid therapy group (p < 0.0001). 17 Despite both groups having similar characteristics, the study is limited by a lack of randomisation as well as unclear criteria used in recruitment. However, Myers and Clough (2014), using liquid Polidocanol in various concentrations found conflicting results with better occlusion rates when treating tributaries (92%) rather than truncal veins (65%) (p < 0.01). 18 Consecutive patients attending for varicose vein treatment were offered ultrasound-guided foam sclerotherapy (UGFS) to refluxing truncal veins (saphenous and non-saphenous). 19 In total, 181 patients were enrolled and reviewed within six weeks of treatment. Approximately 60.0% were females with a median age of 52 years. The occlusion rate was 74% after the first intervention and a further 15% after two interventions. 19 Common complications included phlebitis and pigmentation.
Coleridge-Smith 20 evaluated his own series of 808 patients undergoing UGFS for incompetent truncal veins and, in the 459 patients attending follow-up at six months or greater, demonstrated an occlusion rate of 88% for the GSV and 82% for the short saphenous vein (SSV). Three interventions (each separated by two weeks) were required to achieve an occlusion rate of 99% of the unilateral varices.
When compared to other treatment modalities, foam sclerotherapy proved to be less effective. Rasmussen et al. 1 conducted a randomised controlled trial to compare endovenous laser therapy (EVLT), radiofrequency ablation (RFA), UGFS and surgical stripping in patients with evidence of GSV incompetence. Five-hundred patients were recruited and the follow-up period was for one year. The primary outcome measure was treatment failure, which was defined as an open part of the treated vein segment measuring more than 10 cm in length. The clinical quality of life and radiological change after intervention was also recorded. Baseline characteristics for all four groups did not differ. At one-year follow-up, there were significantly more cases of treatment failures in the UGFS group (16.3%) compared to the other three groups (less than 6%) (p < 0.001). 1 Patients who were treated with either UGFS or RFA reported lower pain scores and returned to their normal activities earlier compared to those receiving EVLT or surgery (p < 0.001). All groups improved similarly in both clinical and quality of life scores. UGFS was also found to be the cheapest treatment method, especially when the cost of being off from work was taken into account.
Lower occlusions rates were again reported in the MAGNA trial. This was a randomised controlled trial comparing EVLT, UGFS and surgery in 223 patients (240 legs). 21 The primary outcome measure was anatomic success on duplex ultrasound examination. At the one-year follow-up, both EVLT and surgery had comparable occlusion rates (88.5% and 88.2%, respectively). The corresponding occlusion rate for UGFS was 72.7% (p < 0.02). All three groups also demonstrated similar improvement in the quality of life scores (CIVIQ and EQ-5D).
Tumescent anaesthesia was used in both the previous two studies in patients receiving endothermal methods. This anaesthetic solution acts as a heat sink for the transmitted heat energy and pushes surrounding tissues away, protecting them from burn injury. 22 It also helps push blood out of the vein and compresses the vein onto the probe, thereby enabling a more effective thermal injury to the vein being treated 21 and, hence, potentially explaining the high occlusion rates observed.
In order to investigate whether these effects are replicated in patients receiving catheter-directed foam sclerotherapy (CDFS), Devereux et al. 23 conducted a prospective randomised clinical trial in which patients received CDFS with or without tumescence. The tumescent fluid used was 0.9% saline only, as the addition of local anaesthesia and adrenaline would have been against the guidelines of the German Federal Institute for Drugs and Medical Devices, the organisation which granted ethical approval for the study. Fifty patients were recruited, with 43 of them attending final followup at 12 months. At the end of the follow-up period, the complete occlusion rate was 74% in the CDFS with tumescent group compared to 75% in the CDFS group only. 23 The authors speculate that the lack of adrenaline in the tumescent might explain the similarities in the level of complete venous occlusion in the two arms of the study. Indeed, they suggest that the addition of adrenaline might have brought about a more potent reduction of the vein diameter and improved the occlusion rates of the CDFS/tumescent group.
The longest data to date following UGFS have been reported by Darvall et al. 24 They described the patientreported outcomes 5-8 years following treatment with UGFS. Out of the initial 351 patients (479 limbs) treated, 285 (81.2%) attended follow-up a minimum of five years later. Using a Kaplan-Meier plot, they estimated the proportion of their cohort requiring retreatment at five years to be 15.3%. There was also significant improvement noted in the Aberdeen Varicose Vein Symptom Severity score (AVSS), similar to that observed at earlier follow ups. The physical component of the short form12 (SF-12 Õ ) was also found to have improved compared to pre-treatment values. The mental component of SF-12 Õ was, however, similar to baseline levels. Between 62.7% and 81.0% reported exceeded or met expectations with respect to social, work or leisure activities. Eighty-two percent of patients were highly satisfied (giving a score of 8 to 10) and more than 90% would recommend the treatment to their family and friends. The same group also demonstrated that, as well as improving the quality of life of patients, UGFS is less painful and leads to earlier return to work compared to surgery. [25] [26] [27] Complications associated with UGFS include phlebitis, skin pigmentation, thromboembolism (pulmonary embolus or deep vein thrombosis) as well as neurological symptoms such as migraines, transient ischaemic attacks or visual disturbances. 19, 28 The occurrence of neurological symptoms has been attributed to the presence of a patent foremen ovale (PFO), a common finding in the population (20-30%). 28 Foam sclerotherapy has also been combined with other methods, notably, surgery and coil insertion, to improve the rate of occlusion of the GSV. One-shot scleroembolisation is one such mechod. 29 In the first article describing its use, nine patients with GSV reflux (six patients with simple varicose veins and three with healed ulcers) were recruited and underwent day case treatment of the incompetent vein. The technique involves the introduction of an endovenous catheter in the GSV and, under ultrasound-guidance, placement of a standard platinum coil 1 cm below the origin of the epigastric vein. The coil is 1 mm wider than the calibre of the SFJ and causes the prompt occlusion of the terminal portion of the GSV. The final step is the injection of sclerofoam (2% Polidocanol), which causes fibrosis and occlusion of the vessel. Post-procedure, elastic bandage was applied to the treated limb. Patients were discharged the same day and advised to wear the compression for 15 days. All of them were followed for up to three months. After one week, one instance of recanalisation was detected, which was successfully treated with foam sclerotherapy. At three months, therefore, all nine patients were asymptomatic and had completely occluded GSV. 29 In addition, no migration of the coil or compression of the CFV was noted and the coil was impalpable. There were no perioperative complications and no incidences of DVT. Advantages of the technique include the fact that it can be carried out under local anaesthetic as a day case procedure and does not require any tumescence. The average cost of the coil was US $120. This technique is promising, but the findings need to be confirmed with larger studies and longer term follow-up.
Ricci et al. 30 described a technique called ultrasound-assisted GSV ligation and division, which is another potential alternative to endothermal treatment. Eighteen patients (20 GSVs) were enrolled. The procedure consists of prior vein marking, initial phlebectomies for varicosities followed by ultrasound-guided extraction and division of the GSV about 3 cm below the SFJ as it courses over the adductor longus (an area relatively free from other structures). Foam sclerosant is then injected through the distal end until it comes out of the distal phlebectomy stab incisions. The proximal end is transfixed, leaving a short stump, while the distal end is ligated. Post-procedure, compression bandaging is applied for one week. At one month, the residual stump was patent in all cases with no evidence of reflux. At six months, one proximal GSV stump showed evidence of reflux originating from a pudental vein. This technique offers the advantage of sparing the junction tributaries and avoiding dissection, hence, possibly giving rise to less stimuli for neovascularisation. Potential problems are the likely difficulty in obese patients and large GSV diameter where the vein is extracted from. Moreover, it cannot be truly considered an NTNT as it still makes use of tumescent anaesthesia. Longer term follow-up as well as a larger cohort is required to confirm findings of this study.
Newer NTNT methods have recently appeared on the market and these are being promoted as offering the potential of higher occlusion rates, while maintaining improved quality of life and earlier return to activities, but without the side-effects of endothermal ablation.
Mechanochemical ablation
A new device, the ClariVein Õ mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA), has been introduced which avoids the use of heat and tumescent infiltration. It combines an endovenous mechanical method using a rotating wire with simultaneous injection of liquid sclerosant. 31 The wire rotates at 3500 rotations per minute, injuring the venous intima while the sclerosant is infused through an opening close to the catheter tip. 31 
Animal studies
Tal et al. 32 tested the MOCA device on 11 male goats (12 veins included) and analysed the histological samples obtained from this caprine model. Four different treatments were examined: group 1: the ClariVein Õ catheter and 1.5% sodium tetradecyl sulphate (STS) (MOCA procedure) (five veins); group 2: ClariVein Õ and 0.9% saline (one vein); group 3: 5 mL injection of 1.5% STS (five veins); and, group 4:5 mL injection of 0.9% saline (one vein). The lateral saphenous vein was selected and duplex ultrasound examinations were carried out pre-operatively and on days 14, 28, 56 and 84 to assess the degree of occlusion. At day 84, all animals were euthanised and underwent gross necropsy. 32 All the veins receiving the MOCA procedure (group 1) demonstrated complete or near complete occlusion on ultrasound assessments at 84 days, while the veins in the other treatment groups were still patent at the end of the study, thereby indicating the superiority of the ClariVein Õ catheter and sclerosant to produce vein occlusion and fibrosis rather than only using liquid sclerosant. Comparison of the saline groups (groups 2 and 4) showed more subintimal impingement and medial fibrosis in group 2 than in group 4. No adventitial fibrosis was demonstrated, however, and veins from both groups remained patent at the end of the study.
One limitation of the study is that the number of veins treated in each group is not equivalent and the question remains as to whether some of the changes noted could have been improved with inclusion of a larger number of veins. This study, in any case, illustrates the superiority of the MOCA procedure in achieving venous occlusion compared to using either the ClariVein Õ catheter alone or liquid sclerosant on its own.
Human trials
In order to determine the safety and efficacy of the ClariVein Õ device, Elias and Raines 31 recruited 29 patients with primary great saphenous vein (GSV) reflux and followed them at four different time points.
Reflux of greater than 0.5 s or longer was determined at the SFJ while patients were in the standing position. A majority of the patients were females (60%) and the average age of the population was 54.3 years (range: 31 to 90 years). The baseline venous clinical severity score (VCSS) was 4.5 with the clinical CEAP (Clinical-Etiological-Anatomical-Pathophysiological) between 2 and 4. The average treatment length was 37.5 cm and the average diameter of the treated veins was 8.1 mm. No patients complained of pain during the ablative procedure. There were no incidences of deep vein thrombosis (DVT), nerve or skin injury. The average follow-up period was 260 days. There was one case (1 out of 30) of recanalization giving a primary closure rate of 96.7% at 260 days. 31 The authors, therefore, concluded that the new ClariVein Õ device was safe and appeared to be effective in the treatment of venous reflux. 31 However, most of the patients recruited had CEAP stage 2 disease (77%) and there were three occurrences of ecchymoses. The authors postulate that this might be secondary to the rotating wire catching on a side branch or valve cusp.
About the same time, van Eekeren et al. 33 conducted a similar study in the Netherlands to assess the applicability and safety of MOCA. Twenty-five patients with primary GSV reflux were recruited (30 limbs), undergoing mechanochemical ablation at two centres. Most of the patients were women (72%) and the mean age of the population was 52 years. The CEAP classification ranged from C2 to C4 and the mean VCSS score was 3.3. The mean duration of the procedure was 20 min and the treated veins were on average 40 cm in length and 6.1 mm diameter at the sapheno-femoral junction. The median maximal pain score was four (interquartile range (IQR) 3-6) on a 10-point scale, while the mean maximum pain measured on day one post-procedure was 9 mm on a 100 mm visual analogue scale (VAS). 33 There were no major adverse events and the minor complications included nine cases of local ecchymosis at the puncture site and four of phlebitis. At the six weeks' follow-up, the GSV was completely obliterated in 87% of cases (26 out of 30 legs treated) starting 2 cm distal to the SFJ at the six weeks' follow-up. Patient satisfaction was 8.5 (IQR 8-9) on a 10-point scale and the median VCSS decreased significantly from 3 to 1 (p < 0.001). 33 The effect of MOCA on the small saphenous vein (SSV) has been studied by the same research team. The SSV accounts for approximately 15% of lower limb truncal venous incompetence. 34 Fifty patients with primary SSV incompetence were enrolled and received MOCA treatment to their incompetent SSV with 1.5% Polidocanol as sclerosant. 34 The primary outcome measures included anatomic success, which was defined as occlusion of the treated vein and recanalised SSV or treatment failure defined as an segment of > 10 cm. The median pain score using a VAS was 2 cm (IQR 2-4 cm) and the median patient satisfaction was 8 (IQR [8] [9] . No major complications were recorded, including no evidence of nerve injury and no DVT. Minor complications were noted, mainly localised ecchymosis and induration and transient superficial thrombophlebitis in 14%. The occlusion rate was 100% (50 out of 50 limbs treated) and 94% (44 out of 47 legs treated) at the six-week and one-year follow-up, respectively. However, it is to be noted that different concentrations of the sclerosant were used to treat the proximal section, with 1.5% Polidocanol for the first 15 patients, but 2 ml of 2% Polidocanol in the subsequent 35 patients (followed by 1.5% for the remainder of the vein). There were two occurrences of recanalisation in patients treated with the lower concentration, compared to one out of those who received 2% Polidocanol.
The same group again evaluated the one-year results of MOCA in patients with GSV insufficiency. 35 Consecutive patients with primary GSV insufficiency were included in the study. Ninety-two patients (106 limbs) were recruited. The mean age was 52 years with 67% of the cohort being females. Treatment failure was defined as a recanalised segment of > 10 cm of the treated GSV. MOCA was performed on 105 legs and the median post-procedural pain using a 0-100 mm VAS during the first 14 days after treatment was 7.4 mm. No major complications were observed, although there were incidences of thrombophlebitis, induration, localised haematoma and mild hyperpigmentation at the puncture site. The occlusion rate immediately post-procedure, at six months and at one year was 100%, 93.2% (96 of 103 limbs treated) and 88.2% (90 of 102), respectively. 35 The mean VCSS score improved significantly at the six month and one-year follow-up (p < 0.001). Compared to baseline, the QoL improved significantly with a mean AVVQ score of 6.6 at six months (p < 0.001) and 2.4 at year one (p < 0.001).
There have been few studies comparing MOCA to endothermal ablation. One of these studies comprised of 68 consecutive patients treated for symptomatic unilateral GSV reflux and their post-operative pain score, as well as early quality of life was assessed. 36 Thirtyfour patients were assigned to either MOCA or radiofrequency ablation (RFA). There were 25 males and 43 females, with a mean age of 58 AE 17 years. There were no significant differences in the baseline patient characteristics. The mean procedural pain during treatment was similar between the two groups (p ¼ 0.16). Patients receiving MOCA reported less pain compared to RFA over the first three days (6.2 mm vs. 20.5 mm; p ¼ 0.004) and during the first 14 days after treatment (4.8 mm vs. 18.6 mm; p < 0.001). 36 They also required less analgesia compared to the RFA group. Patients in both groups who developed post-operative thrombophlebitis and induration had higher pain scores. Treatment time was significantly shorter in the MOCA group (p ¼ 0.02). At six weeks, the median VCSS score improved significantly in both groups (p < 0.001). Quality of life assessment showed that the AVVQ score improved in both the MOCA (p ¼ 0.006) and RFA (p ¼ 0.002). 36 Time to return to normal activities and work was also found to be significantly shorter in the MOCA group. The authors, thus, concluded that post-operative pain is significantly lower after MOCA compared to RFA and the former was associated with a faster return to normal activities and work. This is the first study which has provided direct evidence of the lesser discomfort following varicose vein ablation and earlier return to activities in patients receiving MOCA. But, this was a non-randomised trial and the criteria used for patient selection is not clear. Moreover, the procedural pain score was no different in the two groups, but the authors allude to the fact that their sample size was too small to detect a difference and suggested carrying out a randomised trial.
A multicentre randomised clinical trial (RCT) comparing MOCA to RFA in the treatment of GSV or SSV and looking at the intra-procedural pain scores and improvement in quality of life at one and six months is currently ongoing in our unit. 37 The early results have already been published and 119 patients, having similar baseline characteristics, have been randomised (60 of them to the MOCA group). These results demonstrate significantly lower maximum (19.3 mm versus 34.5 mm) and average VAS pain score (13.4 mm versus 24.2 mm) in the MOCA group compared to the RFA group (p < 0.001 and p ¼ 0.001, respectively). Seventy-eight patients (66%) attended their one-month follow-up appointment. Both clinical and quality of life (QoL) scores had improved by then. However, there was no significant difference in the time taken to return to normal activities and work. The complete/proximal occlusion (occlusion of the whole treated segment or more than 5 cm of the proximal segment) rates at one month was found to be 92% in both groups (p ¼ 0.89). The trial has completed its recruitment phase and is in the final stages of follow-up and analysis.
The MARADONA trial (Mechanochemical endovenous Ablation versus RADiOfrequeNcy Ablation in the treatment of primary great saphenous vein incompetence) has been designed to directly compare the anatomical and clinical success rate at one year compared to RFA and is hoping to recruit 230 patients in each group (460 patients in total). 38 Patients will then be followed up for five years, giving excellent long term data. The results of this are eagerly anticipated and expected in 2020.
Complications of mechanochemical ablation
Reported complications following MOCA include superficial thrombophlebitis, induration along the course of the treated vein, localised haematoma and mild hyperpigmentation at the puncture site. 35 An increasingly recognised adverse event following MOCA is the rotating wire tip getting caught. This may give rise to ecchymoses, patient discomfort or resistance to pullback. 31, 39 However, as reported by Lane et al., 40 rarely it can become stuck with no possibility of dislodgement, with dramatic consequences (the SSV was inverse stripped). There have been no reports of skin necrosis, deep vein thrombosis or nerve injury.
Cyanoacrylate glue
Another tumescentless method recently introduced is the sapheon venaseal closure system (Sapheon Inc., Santa Rosa, Calif, USA), which makes use of cyanoacrylate glue to treat venous incompetence.
What is glue?
The glue used in this tumescentless method is n-butyl cyanoacrylate (n-BCA), which was initially introduced in medical practice approximately 40 years ago. 41 The first cyanoacrylate adhesive used at the time had low tensile strength and was associated with both acute and chronic inflammation. 41 N-butyl cyanoacrylate is an adhesive liquid monomeric agent, which quickly polymerises and becomes solid when it comes into contact with a solution containing anions (e.g. with the hydroxyl groups in blood). 42 This subsequently leads to occlusion, marked inflammatory endothelial response, and, ultimately fibrosis. 42 Further development of the material with the addition of plasticisers and stabilisers has improved its flexibility and reduced its toxicity. 41 This has resulted in cyanoacrylate glue being used more widely, for example, in ophthalmic surgery, cosmetic procedures, dental applications, tissue adhesion and haemostasis of acute bleeding such as endoscopic sclerotherapy of gastric variceal bleeding with high safety profiles reported in patients followed up for 10 years. 43 They have also been used intravascularly in treating type I and II endoleaks of abdominal aortic aneurysm repair procedure, varicocoeles, pelvic congestion syndrome and arterio-venous malformations (AVM). 43 
Animal studies
Kailasnath and Chaloupka 44 developed a bench top testing apparatus that permits direct measurement of evolving binding forces that develop during polymerisation of CA. They compared the rate of polymerisation of CA using a plastic model vessel and a tissue model (common carotid artery of a swine). They found that there were three distinct stages of polymerization. The initial phase (phase I) demonstrated a linear rate of increasing tensile forces lasting less than 10 s followed by phase II, which had a more constant tensile force (lasting up to 1 min). Polymerisation was, however, not achieved in either phases. A final step (phase III) started at the end of the second phase and was characterised by an exponential rise in the tensile forces which leads to complete polymerization. 44 The rate of polymerisation and strength of the binding forces formed were variable and dependent on type and formulation of CA used. 43, 44 The first experiment looking at using CA adhesive as vein closure method in an animal model used the superficial epigastric veins (SEVs) of two swines. 45 The SEVs empty into the abdominal rectus vein (ARV) at the costal margin. The purpose of the experiment was to assess the feasibility of the proposed method as well as evaluating its safety and effect on the vein wall. With the swines under general anaesthetic, the right and left SEVs were cannulated followed by insertion of the CA adhesive delivery catheter (Sapheon, Santa Rosa, California). This venous closure system also incorporates a 3 cc (cubic centimetre) syringe, a dispenser tip and a dispenser gun (Sapheon). 45 The method of treatment used was as follows. The catheter tip was positioned 2 cm distal to the SEV-ARV junction. Pressure was then applied with the ultrasound transducer just cephalad to the catheter tip. Using a slow deliberate trigger pull of 3-s duration, 0.16 mL of CA was delivered to the target vein. The delivery system (sheath plus catheter) was immediately pulled back 3 cm after this initial injection and transverse compression applied for 30 s to allow interaction between CA and the vein wall. This process was repeated every 3 cm until the vein was treated.
Four SEVs were treated in total and the two swines were sacrificed at day 60 post-treatment. 45 The SEVs were harvested and sections were studied macro-and microscopically. Explanted segments from the caudad, middle and cephalad areas were completely occluded with no patent segments. On histology, fibrous tissue and inflammatory cells were present, with one of the three examined sections exhibiting fibrotic projections which caused occlusion of nearly the entire lumen. The wall was segmentally thickened by fibrous tissue and the lumen was dilated by an abundant clear space containing moderate amounts of debris and coalescing, tree-like bands of microphages and spindle cells. The clear space appeared surrounded by multinucleated giant cells, which were presumed to be reacting toward foreign material. Spindle cells with dense eosinophilic matrix replaced the tunica intima and disrupted the tunica media. Additionally, the wall was disrupted by numerous aggregates of histiocytes and lymphocytes with lymphoid follicles. Also, a dark-coloured bulge (entrapped blood) in the vein was observed, though not visible on the skin. The changes observed in the treated veins are consistent with chronic foreign-body-type inflammatory response. Unwanted migration of CA was not found, nor was recanalisation present in any of the treated veins. Evaluation of control segments lacked any significant histologic changes. 45 
Human trials
The first clinical trial of using cyanoacrylate adhesive for the treatment of varicose veins recruited 38 patients with great saphenous vein incompetence in a prospective non-randomised study. 46 Consecutive patients were enrolled and followed up at 48 hand 1, 3, 6 and 12 months after their intervention with a clinical examination and a duplex ultrasound scan. Complete occlusion of the treated segment was considered as treatment success. A disposable Sapheon Closure System (SCS) was used, which included a delivery catheter with hydrophobic properties to prevent CA-mediated adhesion to the vein wall. 46 The catheter was removed after venous closure has been confirmed and a single adhesive bandage was applied. No additional procedures were carried out and no compression stockings or bandages were applied. Approximately three quarters of the patients were females with a median age of 51 years (range: 26-77 years). 46 The mean GSV diameter at the SFJ was 8.0 AE 2.2 mm and the mean length of vein treated was 33.8 AE 9.1 cm. The mean volume of CA glue used was 1.3 mL (range: 0.6-2.3 mL). All the veins treated were completely occluded at the 48-h follow-up. By the 12 months' follow-up, three patients had developed recanalisations of GSV, giving a complete occlusion rate of 92.1%. 46 Seven patients developed post-operative thrombophlebitis, one patient developed cellulitis and one patient had hyperpigmentation at 12 month due to the treated vein being very close to the skin. In addition, eight patients had evidence of thread-like thrombus extension across the SFJ into the common femoral vein (CFV) at the 48-h follow-up (protruding a length of 12.6 AE 9.9 mm). All thrombus extensions had resolved without any anticoagulation by the six months' follow-up. The VCSS scores showed improvement from 6.1 AE 2.7 at baseline to 1.5 AE 1.4 at 12 months (p < 0.0001). This study set out to determine the feasibility of using CA in the treatment of saphenous vein incompetence. It also demonstrated an occlusion rate comparable to those of endothermal ablation methods in use. Patients were seen again at the 12 and 24 months' period. 46 Three patients presented with a GSV recanalisation of more than 5 cm at one, three and six months, respectively, with the occlusion rate at the 24 months' mark using a life-table analysis being 92%. 47 The VCSS score at 24 months was lower than baseline, although it was still higher than the score at six months. These results demonstrate that CA is potentially an alternative to the endothermal methods, especially as no tumescent is needed. No compression therapy is prescribed since the technique does not cause perforation of the vein wall. Two of the authors had connections with the funding company, Sapheon Inc., and with consulting firms with an interest in the device.
Proebstle et al. 48 undertook a prospective, multicentre clinical trial of endovenous CA embolisation of refluxing GSVs in seven centres across Europe. 47 Symptomatic patients with GSV incompetence confirmed on duplex ultrasound were recruited and treated with CA, starting at 5 cm distal to the SFJ. This distance was selected as it would provide enough space for the ultrasound compression between the delivery catheter and SFJ, as well as to enable glue propagation toward the SFJ following injections. No post-procedure compression was used. No adjunctive treatment or reintervention was undertaken for three months after the intervention. Clinical and quality of life assessments were carried out at baseline, and patients were followed up at 48 h and at 1, 3, 5 and 12 months initially. Seventy patients were enrolled in total with 79% of them being females. The mean age was 48.4 years (range: 22-72 years). The mean diameter of the GSV at the SFJ was 7.8 mm and the mean length was 37.6 cm. The mean treatment time was 18.6 min (range: 8-74 min). Using a life-table method, the complete occlusion (defined as no patent segment of more than 10 cm) rate was 92.9% at the 12 months' follow-up point. 48 The patients' clinical and QoL scores were significantly improved. The most common adverse events were phlebitic reaction, occurring in eight limbs. A single patient had a 6 mm extension of thrombus into the common femoral vein. This was successfully treated with low molecular weight heparin. Thus, this study demonstrated that CA was safe and effective in the treatment of GSV reflux and an RCT comparing the technique to endothermal methods have been advocated.
In the VeClose trial, a multicentre randomised controlled trial comparing cyanoacrylate embolisation and radiofrequency ablation for refluxing great saphenous veins, two hundred and twenty-two patients were recruited and randomised to receiving CA or RFA. 49 All patients were prescribed compression stockings to wear continuously for three days and only during waking hours for an additional four days. The primary study end-point was complete closure of the GSV defined as closure of the entire treated vein with no discrete patent segments of more than 5 cm. All patients were followed up for three months. Prespecified models were used to impute missing data. Most patients were females (79%) and Caucasian (94%) with the most common CEAP clinical class being 2 and 3. The mean age was 49.0 years and 50.5 years for CA and RFA, respectively. The occlusion rate in both groups was 100% at day 3. At the three-month point, the occlusion rates were 99% for CA and 96% for the RFA group. However, this was obtained using predictive statistical models to compensate for missing data (31/222). At three months, VCSS, AVVQ and generic quality of life all showed significant improvement compared to baseline (3.5, p < 0.01; 8, p < 0.01 and 0.03, p ¼ 0.01, respectively). There was a non-significant increased incidence of phlebitis in the CA group (20 vs. 15 events, p ¼ 0.36). Most of these cases were mild and were successfully treated with over-the-counter non-steroidal anti-inflammatory agents. There was, however, also less ecchymosis at day 3 in the CA group compared to the RFA group with 94.5% of patients from the CA group having bruising in less than 25% of the treated length (8.2 cm) compared to 81.5% of the RFA group (8.8 cm) (p < 0.01). Venous access and mean intraprocedural pain scores for both methods were similar. Multiple imputation models showed non-inferiority with both optimistic and pessimistic models.
Complications of CA
The most commonly reported complications of CA use for the treatment of varicose vein disease, so far, include ecchymosis and phlebitis. 49 In the first trial of this technique, thread-like thrombus extensions were noted. 45 It was hypothesised that this was probably due to the catheter being positioned 3 cm from the SFJ and not offering enough space for the glue to propagate along the GSV. 46 In subsequent trials, this distance was increased with resultant improvement in the rate of this complication and the acceptable distance in contemporary practice is now 5 cm. 48, 49 CA injection, when used in the treatment of gastric varices, poses the risk of systemic embolisation, with reported cases of pulmonary embolism, stroke and multi-organ infarction via a patent foramen ovale, or even recurrent sepsis caused by the embolised CA glue acting as a septic focus. 50 These latter adverse events have not been reported thus far with CA use in varicose veins.
Conclusion
So far, mechanochemical ablation and cyanoacrylate glue have been shown to be at least equivalent to endothermal techniques and probably superior to UGFS with respect to occlusion rates. They also appear to offer better comfort and earlier return to normal activities. Despite their undeniable promise, further randomised controlled trials with longer followup will hopefully be able to provide more robust evidence of their respective merits.
